2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Recruiting
13
Active not recruiting
8
Completed
7
Terminated
3
Unknown
2
Not yet recruiting
2
Withdrawn
1
No longer available
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
1
Gastrointestinal
1
Breast
1
Conditions
Gastrointestinal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Lobular
1
Breast Neoplasms
1
Interventions
Cisplatin
512
Radiotherapy
376
Cyclophosphamide
361
Carboplatin
354
Capecitabine
341
Oxaliplatin
331
Paclitaxel
328
Gemcitabine
318
Docetaxel
314
Fluorouracil
288
Drug Therapy
271
apatinib
245
Bevacizumab
243
camrelizumab
217
Etoposide
200
Irinotecan
182
Doxorubicin
180
Leucovorin
160
Dexamethasone
160
pembrolizumab
150
sintilimab
143
Neoadjuvant Therapy
142
anlotinib
139
Pemetrexed
138
Cytarabine
138
Blood Specimen Collection
138
Surgical Procedures, Operative
130
toripalimab
128
Radiosurgery
127
S 1 (combination)
124
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Unknown
×
entrectinib
×
Clear all
NCT04551495
2024-12-04
ROSALINE
Jules Bordet Institute
Phase 2
Unknown
65 enrolled
NCT04591431
2023-10-03
ROME
Fondazione per la Medicina Personalizzata
Phase 2
Unknown
400 enrolled